Related Experiment Videos
[Polyvalent intravenous immunoglobulins in systemic lupus]
1Service de médecine interne, Hôpital de la Pitié-Salpêtrière, Paris, France.
La Revue De Medecine Interne
|October 16, 1999
Purpose:
To evaluate intravenous immunoglobulins (IVIG) treatment, which is immunomodulatory but not immunosuppressive, in SLE.
Main Issues:
IVIG indications in SLE could be categorized as already validated as for chronic polyradiculoneuropathy or thrombocytopenia; failure of classical treatment in threatening active disease; undetermined manifestation as reactive hemophagocytic syndrome which could be both disease-specific or iatrogenic, infection-related. To date, no published study has firmly established the efficacy of IVIG in SLE.
Conclusion:
IVIG therapy in SLE should be evaluated in prospective trials.